IGM Biosciences (IGMS) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
1 Feb, 2026Opening remarks and agenda
The meeting was convened to seek stockholder approval on key proposals, with board members and external advisors introduced.
The Inspector of Election was appointed to oversee voting and ensure impartiality.
Shareholder proposals
Four proposals were presented: election of three Class Two directors, ratification of the independent auditor, amendment to limit officer liability, and approval of a stock option exchange program for employees (excluding CEO and non-employee directors).
Overview of voting outcomes
All three director nominees received over 90% of votes in favor.
Ratification of Deloitte & Touche, LLP as auditor received over 99% approval.
Amendment to limit officer liability was approved by over 83% of votes.
Stock option exchange program for employees was approved by over 96% of votes.
All proposals passed by majority and will be reported in a Form 8-K filing.
Latest events from IGM Biosciences
- Key trials fully enrolled; IgM platform targets autoimmune safety and efficacy, with pivotal data ahead.IGMS
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Initial autoimmune data for T-cell engagers expected by late 2024, with adaptive trial strategies.IGMS
Stifel 2024 Immunology and Inflammation Virtual Summit20 Jan 2026 - Exclusive focus on autoimmunity, new CEO, and key clinical data expected by early 2025.IGMS
Status Update20 Jan 2026 - T-cell engagers advance in autoimmune trials, with robust data expected by mid-2025.IGMS
Guggenheim's Inaugural Healthcare Innovation Conference15 Jan 2026 - Imvotamab's clinical progress in autoimmunity sets the stage for a pivotal mid-2025 data update.IGMS
Stifel 2024 Healthcare Conference13 Jan 2026 - Focused on autoimmunity, advancing imvotamab with robust data expected mid-2025.IGMS
Jefferies London Healthcare Conference 202413 Jan 2026 - Q2 2025 net income surged to $97.6M on Sanofi revenue recognition and restructuring actions.IGMS
Q2 202531 Jul 2025 - Strategic shift to autoimmunity, lower R&D costs, and cash runway projected into 2027.IGMS
Q3 202413 Jun 2025 - Clinical progress, lower losses, and strong liquidity support key data readouts in 2025.IGMS
Q2 202413 Jun 2025